Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2003
09/18/2003CA2478931A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
09/18/2003CA2478921A1 Novel chalcone derivatives and uses thereof
09/18/2003CA2478897A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions
09/18/2003CA2478706A1 Oxo-azabicyclic compounds
09/18/2003CA2478369A1 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
09/18/2003CA2478245A1 Treatment and prevention of inflammatory disorders
09/18/2003CA2478065A1 Macrocyclic compounds useful as pharmaceuticals
09/18/2003CA2478026A1 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline
09/18/2003CA2477984A1 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
09/18/2003CA2477973A1 Methods for alzheimer's disease treatment and cognitive enhancement
09/18/2003CA2477949A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation
09/18/2003CA2477701A1 Controlled release dosage forms
09/18/2003CA2477675A1 Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
09/18/2003CA2477393A1 Ibuprofen solution for hard shell capsules
09/18/2003CA2476031A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
09/18/2003CA2475254A1 Pyridinyloxy derivatives as 5-ht receptor ligands
09/18/2003CA2474771A1 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
09/18/2003CA2474613A1 Sustained release drug formulations containing a carrier peptide
09/18/2003CA2423259A1 New compounds derived from quinazoline, the process for preparing them, and the pharmaceutical compositions containing them
09/17/2003EP1344823A1 Novel g protein-coupled receptor proteins and dnas thereof
09/17/2003EP1344779A1 Azolo-pyrimidines
09/17/2003EP1344523A1 Ibuprofen solution for hard gelatin capsules
09/17/2003EP1344522A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
09/17/2003EP1343900A2 Oxidoreductases
09/17/2003EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases
09/17/2003EP1343818A1 Modified tachykinin receptors
09/17/2003EP1343813A1 Novel compounds
09/17/2003EP1343791A2 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
09/17/2003EP1343788A1 Imidazo-triazine derivatives as ligands for gaba receptors
09/17/2003EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives
09/17/2003EP1343784A2 Urea substituted imidazoquinoline ethers
09/17/2003EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
09/17/2003EP1343778A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
09/17/2003EP1343775A2 Piperazine derivatives
09/17/2003EP1343773A1 Thiazole derivatives for traeing ppar related disorders
09/17/2003EP1343769A1 Benzoylpyridazines
09/17/2003EP1343768A1 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
09/17/2003EP1343764A1 Urea and urethane derivatives as integrin inhibitors
09/17/2003EP1343760A2 Muscarinic antagonists
09/17/2003EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands
09/17/2003EP1343757A1 Indole derivatives
09/17/2003EP1343756A2 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
09/17/2003EP1343751A2 Cyclic derivatives as modulators of chemokine receptor activity
09/17/2003EP1343746A1 Carboxylic acid compound having cyclopropane ring
09/17/2003EP1343561A1 Serine protease inhibitors
09/17/2003EP1343529A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
09/17/2003EP1343528A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
09/17/2003EP1343527A2 Adjuvant combination formulations
09/17/2003EP1343526A2 Vaccine
09/17/2003EP1343520A2 New therapeutic uses of smr1 peptides
09/17/2003EP1343519A2 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
09/17/2003EP1343517A2 Survical promoting ncam binding and ncam ligand biding compounds
09/17/2003EP1343509A2 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
09/17/2003EP1343505A1 Cxcr3 antagonists
09/17/2003EP1343504A2 Pharmaceutical formulation of gepirone for oral administration
09/17/2003EP1343501A1 Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
09/17/2003EP1343498A1 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
09/17/2003EP1343495A2 Methods of treating anxiety disorders
09/17/2003EP1343490A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof
09/17/2003EP1343488A1 Treatment of statin side effects
09/17/2003EP1343479A2 Aerogel powder therapeutic agents
09/17/2003EP1314426A9 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
09/17/2003EP1282622B1 Crf receptor antagonists and methods relating thereto
09/17/2003EP1244452B1 Carboxamide derivates of pyrrolidine and piperidine as urotensin-ii receptor antagonists
09/17/2003EP1224174B1 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
09/17/2003EP1200445B1 Thienopyranecarboxamide derivatives
09/17/2003EP1196411B1 Bradykinin b1 receptor antagonists
09/17/2003EP1187627B1 Uses of h-trek-1 polypeptides and polynucleotides encoding them
09/17/2003EP1183241B1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
09/17/2003EP1169056B1 Caspase-8 inhibitors for immunosuppression.
09/17/2003EP1147119B1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
09/17/2003EP1123296B1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
09/17/2003EP1117394B1 Use of carnitines and resveratrol to produce a composition for the prevention or therapeutic treatment of cerebral disorders brought about by ageing and use of neurotoxic drugs
09/17/2003EP1105132B1 The use of r(+)-g(a)-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of obstructive sleep apnea
09/17/2003EP1100471B1 Compressed compositions comprising clarified xanthan gum
09/17/2003EP1095021B1 Quinoline derivatives
09/17/2003EP1079828B1 Compositions comprising 5-hydroxyindole as a modulator of a nicotinic receptor
09/17/2003EP1060242A4 Purified populations of stem cells
09/17/2003EP1049697B1 Triazolo-pyridazine derivatives as ligands for gaba receptors
09/17/2003EP1049672B1 Azetidinecarboxamide derivatives for treating cns disorders
09/17/2003EP0996446B1 Novel substituted imidazole compounds
09/17/2003EP0977737B1 Crf antagonistic quino- and quinazolines
09/17/2003EP0946179B1 Use of olanzapine or a pharmaceutically acceptable salt for the manufacture of a medicament for the treatment of autism and mental retardation
09/17/2003EP0910566B1 Heterocyclic compounds and their preparation and use
09/17/2003EP0909184B1 Targeted drug delivery using sulfonamide derivatives
09/17/2003EP0891329B1 Peptidyl compounds having mmp and tnf inhibitory activity
09/17/2003EP0571613B1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
09/17/2003CN1443197A Acid-modified arabinogalactan protein composition
09/17/2003CN1443190A Matrix metalloproteinase inhibitors
09/17/2003CN1443188A Process for preparation of 9-amino substituted 9,10-dihydropyrrolo [2,1-b] [1,3] benzotiazepines
09/17/2003CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function
09/17/2003CN1443184A 嘧啶衍生物 Pyrimidine derivatives
09/17/2003CN1443178A (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl] -4-morpholibenzamide
09/17/2003CN1443173A Substituted imidazoles as TAFI a inhibitors
09/17/2003CN1443170A Capsaicin receptor ligands
09/17/2003CN1443168A 5-chloro-3-(4-methane sulfonylphenyl)-6-methyl-[2,3'] bipyridine and process for synthesis
09/17/2003CN1443167A Azacyclic compounds for use in treatment of 5-serotonin related diseases
09/17/2003CN1443166A 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3, 4-diol
09/17/2003CN1443164A Pyrrolidine derivatives as metalloprotease inhibitors
09/17/2003CN1443163A Pyrrolidine-2-carboxylic acid hydrozide derivatives for use as metalloprotease inhibitors
1 ... 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 ... 1833